# Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma

> **NCT00226915** · PHASE3 · COMPLETED · sponsor: **Japanese Gynecologic Oncology Group** · enrollment: 637 (actual)

## Conditions studied

- Epithelial Ovarian Cancer
- Primary Peritoneal Cancer
- Fallopian Tube Cancer

## Interventions

- **DRUG:** Paclitaxel+Carboplatin
- **DRUG:** Paclitaxel+Carboplatin

## Key facts

- **NCT ID:** NCT00226915
- **Lead sponsor:** Japanese Gynecologic Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 637 (ACTUAL)
- **Last updated:** 2020-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00226915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00226915, "Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00226915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*